Amarin los­es patent ap­peal and their brief grip on a car­dio­vas­cu­lar, fish oil em­pire

5 years ago
Pharma

News brief­ing: Io­n­is reads out pos­i­tive da­ta for prekallikrein-tar­get­ing drug; PPD col­lab­o­rates on lu­pus re­search

5 years ago
News Briefing

BIO and a string of CEOs is­sue a call for FDA in­de­pen­dence and against sci­ence-by-press-re­lease

5 years ago
Pharma
FDA+

Ake­bia shares MACEd as their PhI­II ane­mia drug fails on safe­ty, of­fer­ing ri­val Fi­bro­Gen a huge ad­van­tage

5 years ago
R&D

New tar­get­ed ther­a­py ap­proach­es win Rain Ther­a­peu­tics $63M — de­signed to beat a quick path to ap­proval

5 years ago
Financing
Startups

As Covid re­search heats up, J&J re­tires a BAR­DA-fund­ed flu an­tivi­ral they worked on for 7 years

5 years ago
R&D
Coronavirus

Re­searchers teamed up to de­vel­op a 'three in one' HIV treat­ment — and the NIH is throw­ing in $14.6M

5 years ago
Discovery
Cell/Gene Tx

Crossover round? Check. Top team? Check. Taysha sails to an IPO with $100M ini­tial ask

5 years ago
Financing
Cell/Gene Tx

Covid-19 roundup: Al­bert Bourla says Pfiz­er PhI­II is at 23,000 pa­tients, sub­mis­sion com­ing end of Oc­to­ber

5 years ago
R&D
Coronavirus

Game change: A fron­trun­ner in the cell ther­a­py 2.0 field of­fers a first look at their lead ther­a­py. And it’s a ...

5 years ago
Cell/Gene Tx

Com­ing up be­hind the mR­NA lead­ers, Sanofi, GSK piv­ot in­to PhI/II tri­al for their tra­di­tion­al tech ap­proach to a ...

5 years ago
R&D
Coronavirus

Amy­lyx spot­lights a PhII suc­cess in slow­ing ALS pro­gres­sion. And they’re tak­ing it to the FDA

5 years ago
R&D

Build­ing up its AI op­er­a­tions, GSK opens a $13M Lon­don hub with plans to woo tal­ent now trekking to Sil­i­con Val­ley

5 years ago
AI

News brief­ing: Amar­in's pan­el could put Vas­cepa patents in jeop­ardy; San­thera nabs a Duchenne drug

5 years ago
News Briefing

En­thused by PhII au­toim­mune da­ta, J&J kept Mo­men­ta wait­ing in the lead-up to $6.5B buy­out

5 years ago
Deals

FDA sends warn­ing let­ter to My­lan over 'i­nad­e­quate' man­u­fac­tur­ing process­es at In­dia plant

5 years ago
FDA+

Weeks af­ter launch, Alex Zha­voronkov's AI-in­spired longevi­ty spin­out sells to Hong Kong-list­ed group

5 years ago
Deals
AI

Bris­tol My­ers snares an­oth­er ap­proval from the old Cel­gene pipeline, nab­bing an over­looked OK

5 years ago
Pharma
FDA+

A pair of Bay Area biotech up­starts with deep pock­ets and a shared in­ter­est in cu­ra­tive can­cer drugs join R&D forces

5 years ago
Startups
R&D

Cas­din goes all-in on the SPAC game with $385M of­fer­ing

5 years ago
Financing
Deals

Covid-19 roundup: KHN: Fau­ci says Covid vac­cine tri­als could end ear­ly, if...; HHS plans $250M cam­paign to 'de­feat ...

5 years ago
Coronavirus

An­oth­er Big Phar­ma 'lif­er' in the top ranks of R&D is start­ing a new chap­ter in biotech

5 years ago
People
R&D

Spurned by the FDA, In­ter­cept brings out the bud­get axe and chops 170 jobs

5 years ago
Pharma

House Over­sight Com­mit­tee sub­poe­nas Ab­b­Vie over 'woe­ful­ly in­ad­e­quate' doc­u­ment pro­duc­tion in price-goug­ing probe

5 years ago
Pharma
First page Previous page 805806807808809810811 Next page Last page
A service from the Financial Times